Organon & Co.

OGN · NYSE

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▼ 0.0% below current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.5%

Institutions85.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$6.22B	$6.40B	$6.26B	$6.17B	$6.30B
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$2.90B	$2.69B	$2.52B	$2.29B	$2.38B
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$3.31B	$3.71B	–	–	–
Gross profit as a percentage of revenue.	53.3%	58.0%	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$187.00M	$864.00M	$1.02B	$917.00M	$1.35B
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.72	$3.36	$4.01	$3.61	$5.33
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.72	$3.33	$3.99	$3.59	$5.31

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$574.00M	$675.00M	$693.00M	$706.00M	$737.00M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$12.87B	$13.10B	$12.06B	$10.96B	$10.68B
All of the company's interest-bearing borrowings, short and long term combined.	$8.64B	$8.88B	$8.76B	$8.91B	$9.13B
Everything the company owes — debt, unpaid bills, and other obligations.	$12.12B	$12.63B	$12.13B	–	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$752.00M	$472.00M	-$70.00M	-$892.00M	-$1.51B

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$700.00M	$939.00M	$799.00M	$858.00M	$2.16B
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$162.00M	$175.00M	$251.00M	$196.00M	$192.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$538.00M	$764.00M	$548.00M	$662.00M	$1.97B

	You	Peer avg
P/E	17.7	12.5
Revenue Growth	-2.3%	+13.6%
ROE	24.0%	-45.0%

Organon & Co.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Related Market Insights

Sun Pharma's $11.75 Billion Acquisition of Organon Marks a Landmark Pharma Deal

Sun Pharma Announces $11.75 Billion Acquisition of Organon in Major Healthcare M&A Deal

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison